Study to Test GSK256073 in Patients With Dyslipidemia

Inclusion Criteria: * Signed written informed consent prior to beginning study-related procedures. Subjects must understand the aims, investigational procedures and possible consequences of the study and must be able to understand and comply with protocol requirements, instructions and protocol-stated restrictions. * Male or female 18-75 years of age at screening. * A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea. * Male subjects must agree to use one of several pre-specified contraception methods. This criterion must be followed from the time of the first dose of study medication until three days following the last dose. * Body weight \> 50 kg (110 pounds) and body mass index (BMI) between 19 and 39 (inclusive) * LDLc concentration ≥100 mg/dL at screening and within 4 weeks of randomization (if screening occurs \> 4 weeks prior to randomization) * Fasting triglyceride concentration ≤ 300 mg/dL at screening and within 4 weeks of randomization (if screening occurs \> 4 weeks prior to randomization) * HDLc ≤ 45 mg/dL for males or ≤ 55 mg/dL for females at screening and within 4 weeks of randomization (if screening occurs \> 4 weeks prior to randomization) * Subject currently receiving lipid-modifying medication(s) must agree to stop medication(s) for at least 6 weeks prior to randomization. Afte…